Research Funded

Mechanisms of Arginine Starvation Induced Cell Death

Brian Van Tine, PhD, Washington University in St. Louis, MD
Recipient of the: $50,000 St. Louis Cure Sarcoma 6k Research Award

Abstract: PEGylated Arginine Deiminase (ADI-PEG20) is a therapeutic that degrades extracellular arginine.  In tumors like sarcoma that cannot make their own arginine due to a urea cycle defect, this agent put tumors into a starvati... Read More

Hippo pathway targeting in uterine leiomyosarcoma

Annalisa Astolfi, PhD, University of Ferrara
Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Leiomyosarcoma is the most common type of uterine sarcoma (uLMS), with an annual incidence of slightly less than two women per 100,000, characterized by a very poor response to standard therapies and an aggressive clinical... Read More

Genomewide therapeutic target screens in novel preclinical models of liposarcoma

Wantong Yao, PhD, The University of Texas MD Anderson Cancer Center
Recipient of the: $50,000 Jay Vernon Jackson Memorial Research Award

Abstract:  Liposarcoma is one of the most common soft-tissue sarcomas, with well-differentiated/dedifferentiated liposarcoma subtype forming the majority of cases. Although recurrences are frequent, surgery remains the mainstay of ... Read More

Enhanced NK cell Immunotherapy for Treatment of Chemotherapy Refractory Sarcoma

Daniel Vallera, PhD, University of Minnesota – Twin Cities
Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Radiation therapy is a crucial treatment modality required to control soft tissue and advanced bone sarcomas. Despite technological advancements used to treat radioresistant sarcomas, local recurrence and metastasis contin... Read More

MCL-1 inhibition unmasks BCL-2 addiction in synovial sarcoma

Anthony Faber, PhD, Virginia Commonwealth University
Recipient of the: $50,000 Zach Cohen Memorial Research Award

Abstract: Metastatic Synovial Sarcoma (mSS) is frequently diagnosed in teenagers and young adults and continues to be treated with polychemotherapy with variable success. The SS18-SSX gene fusion is pathogenomic for the disease, and... Read More

Identification of novel drug targets and predictors of clinical outcomes in desmoplastic small round cell tumors using next-generation sequencing

Madelyn Espinosa-Cotton, PhD, Memorial Sloan-Kettering Cancer Center
Recipient of the: $50,000 Zach Cohen Memorial Research Award

Abstract: Desmoplastic small round cell tumor (DSRCT) is a rare, highly-aggressive soft-tissue sarcoma with an overall five-year survival rate of less than 30%. Next generation sequencing (NGS) has given cancer researchers unprecede... Read More

Unraveling the tumor immune microenvironment of angiosarcomas

Yvonne Versleijen-Jonkers, PhD, Radboud University Nijmegen Medical Center
Recipient of the: $50,000 Catherine Malatesta Memorial Research Award

Abstract: Is immune checkpoint inhibition the solution for angiosarcoma patients? Genetic and immune profiles of angiosarcoma subtypes will lead to novel insights for the design of individualized immune checkpoint-based therapy for ... Read More

Identifying mechanisms of osteosarcoma chemoresistance that arise from the lung metastatic niche

Ryan Roberts, MD, PhD, The Research Institute at Nationwide Children’s Hospital
Recipient of the: $50,000 Pittsburgh Cure Sarcoma Research Award

Abstract: A therapy preventing the emergence of lung metastasis in adolescents with osteosarcoma could save more than 70% of the lives currently lost to this disease. This would represent the most significant improvement in outcome ... Read More